Two publications from the past week:

• Whole-Exome Sequencing’s Cost-Effectiveness in Children with Increasing Neurological Problems | link
• Preferences for pharmacogenomic testing in polypharmacy patients: a discrete choice experiment | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Two publications from the past week:

• Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness? | link
• A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Three publications from the past week:

• Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands | link
• The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA | link
• Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Three publications from the past week:

• A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials | link
• Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation | link
• Applying the Clinician-reported Genetic testing Utility InDEx (C-GUIDE) to genome sequencing: further evidence of validity | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Nine publications from the past two weeks:

• Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions | link
• Reduced resource utilization with early use of next-generation sequencing in rare genetic diseases in an Asian cohort | link
• Resource allocation in genetic and genomic medicine | link (the rest of this Special Issue is available here)
• Correspondence on “Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions” by Lavelle et al | link
• Response to Grosse and Gudgeon | link
• Economic Aspects in Precision Medicine and Pharmacogenomics | link
• Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk | link
• Epistemic justice, African values and feedback of findings in African genomics research | link
• Reduced resource utilization with early use of next-generation sequencing in rare genetic diseases in an Asian cohort | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Two publications from the past week:

• Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis | link
• Early cost-utility analysis of genetically-guided therapy for patients with drug-resistant epilepsy | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

One publication from the past week:

• Managing the introduction of genomic applications into the National Health Service: A special challenge for health technology assessment in Italy | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Three publications from the past week:

• Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation | link
• Health technology assessment of whole genome sequencing in the diagnosis of genetic disorders: a scoping review of the literature | link
• The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications from the past week:

• Cost-Effectiveness of Exome Sequencing versus Targeted Gene Panels for Prenatal Diagnosis of Fetal Effusions and Non-Immune Hydrops Fetalis | link
• Preferences for a polygenic test to estimate cancer risk in a general Australian population | link
• Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer | link
• Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.

Four publications from the past week:

• Economic evaluation of genomic/genetic tests: a review and future directions | link
• Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis | link
• Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States | link
• Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States | link

I’m happy to share any other publications from this week that I’ve missed – just let me know. I publish these updates weekly, on a Tuesday, but only if I’ve seen relevant publications. If you don’t see an update on a Tuesday, assume it has been a quiet week for publications in health economics and genomics.